Ms. Susan Pietropaolo report

LEADING INDEPENDENT PROXY ADVISORY FIRM GLASS LEWIS ENDORSES APTOSE PLAN OF ARRANGEMENT; SHAREHOLDERS ARE RECOMMENDED TO VOTE "FOR" THE APTOSE BIOSCIENCES

Aptose Biosciences Inc. proxy advisory firm Glass, Lewis & Co. has recommended that Aptose shareholders vote "for" a special resolution to approve the previously announced arrangement pursuant to which Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd., a wholly owned subsidiary of Hanmi, will acquire all of the issued and outstanding common shares of Aptose that are not currently owned or controlled by the Hanmi purchasers or their respective affiliates.

Glass Lewis also recommended approval of a continuance that will result in the company continuing from a corporation governed under the Canada Business Corporations Act (CBCA) to a corporation continued under the Business Corporations Act (Alberta) (ABCA).

Your vote is important -- please vote "for" today

The proxy voting deadline is 11 a.m. (EST) on Friday, March 27, 2026.

Vote today

Shareholders are reminded to submit their proxies ahead of the proxy voting deadline. The proxy voting deadline is 11 a.m. (Eastern Time) on Friday, March 27, 2026. Shareholders are encouraged to vote well in advance of the deadline to ensure their vote is submitted in a timely manner.

Details of the meeting

A special meeting of shareholders to seek approval of the arrangement and the continuance, has been reconvened to March 31, 2026, at 11 a.m. (EST). The reconvened meeting will be held virtually via live audio webcast on-line. The meeting was postponed to address comments raised by the United States Securities and Exchange Commission (SEC) on the company's transaction statement on Schedule 13E-3, as amended. The record date for the reconvened meeting was the close of business on Feb. 24, 2026.

Aptose has prepared and filed with the SEC a definitive proxy statement for the reconvened meeting. A copy of the proxy statement has been mailed to all shareholders of the company. The proxy statement, form of proxy, letter of transmittal, as well as Schedule 13E-3, as amended, will also be available for download under Aptose's profile on SEDAR+ and EDGAR in the U.S.

On Dec. 12, 2025, Aptose obtained an interim order from the Court of King's Bench of Alberta authorizing the holding of the meeting and matters relating to the conduct of the meeting.

All shareholders who wish to attend the reconvened meeting must follow the procedures set out in the proxy statement. Shareholders who are unable to attend the reconvened meeting are strongly encouraged to complete, date, sign and return the form of proxy (in the case of registered shareholders) or voting instruction form (in the case of non-registered shareholders) provided with the meeting materials so that as many shareholders as possible are represented and vote at the reconvened meeting.

Shareholder questions and voting assistance

Aptose has retained Morrow Sodali (Canada) Ltd. to assist the company in connection with shareholder communications and proxy solicitation. Shareholders who have questions or require voting assistance may contact Sodali & Co at:

Call toll-free (North America):  1-833-711-4830

Call collect outside North America:  1-289-695-3075

E-mail:  assistance@investor.sodali.com

About Aptose Biosciences Inc.

Aptose is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company's lead clinical-stage compound TUS is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory AML and is being developed as a frontline triplet therapy in newly diagnosed AML.

We seek Safe Harbor.